title: Comparison of different regimens of human gonadotropins for superovulation of rhesus monkeys: ovulatory response and subsequent luteal function.
abstract: This study was designed to identify suitable treatment regimens of human gonadotropin for superovulation of rhesus monkeys. At menses, female monkeys were given one of three regimens: Plan A [days 1 to 6, 60 IU human follicle-stimulating hormone (hFSH); days 7 to 9, 60 IU hFSH/60 IU human luteinizing hormone (hLH)], Plan B [days 1 to 3, 75 IU FSH/20 IU LH; days 4 to 6, 60 IU FSH/20 IU LH; days 7 to 9, 45 IU FSH/45 IU LH], or Plan C [days 1 to 9, 60 IU FSH/60 IU LH]. On day 10, human chorionic gonadotropin (hCG; 1000 IU) was administered. Serum estrogen levels peaked on the day of hCG treatment (day 10) in Plans A and C but earlier (day 8) in Plan B. An oviduct lavage recovered 1 to 3 oocytes in Plan B but 3 to 13 oocytes in the other treatment groups. Peak progesterone levels in the luteal phase were greater (P less than 0.05) in animals receiving Plan A or C than Plan B. Regardless of treatment group, progesterone levels declined abruptly 7 days after ovulation induction; the length of the luteal phase in all groups was significantly less than that of normal menstrual cycles. We conclude that regimens of hFSH and hLH (i.e., Plans A and C), followed by hCG, reliably superovulate rhesus monkeys. However, the premature decline in luteal function around the typical time of implantation may compromise pregnancy initiation and maintenance.
authors.affiliation: Division of Reproductive Biology and Behavior, Oregon Regional Primate Research Center, Beaverton 97006.
authors.forename: C A
authors.initials: CA
authors.lastname: Vandevoort
authors.forename: W L
authors.initials: WL
authors.lastname: Baughman
authors.forename: R L
authors.initials: RL
authors.lastname: Stouffer
mesh_terms: D000818:Animals; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000494:pharmacology; D003338:Corpus Luteum / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage / Q000494:pharmacology; D006062:Gonadotropins / Q000008:administration & dosage* / Q000494:pharmacology; D007986:Luteinizing Hormone / Q000008:administration & dosage / Q000494:pharmacology; D008253:Macaca mulatta; D010062:Ovulation Induction / Q000379:methods*; D010331:Paternal Age; D011374:Progesterone / Q000097:blood; D013480:Superovulation
chemical_list: D006063:Chorionic Gonadotropin; D006062:Gonadotropins; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone